Roivant Sciences Ltd. — Director's Dealing 2025

Jul 30, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2025-07-29

Reporting Person: Torti Frank (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$11.03	2028-09-19	Common Shares (1606249)		Direct
Stock Option (Right to Buy)	$11.5	2029-04-21	Common Shares (585240)		Direct
Stock Option (Right to Buy)	$10.08	2029-08-19	Common Shares (146310)		Direct
Stock Option (Right to Buy)	$13.07	2030-05-19	Common Shares (219465)		Direct
Stock Option (Right to Buy)	$10	2031-05-01	Common Shares (562731)		Direct
Stock Option (Right to Buy)	$10	2031-05-01	Common Shares (1125460)		Direct
Stock Option (Right to Buy)	$3.85	2032-04-19	Common Shares (6026184)		Direct

Footnotes

F1: Reflects an award of stock options to purchase Common Shares that is fully vested.

F2: Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).